Most adults with obesity but without diabetes stop GLP-1 drugs within a year

Overview Debates Related claims Topics Sources

From the articleDiscontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

552c7ae14Article

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

JAMA Network Open cohort study of 125,474 US adults finding that 64.8% of those without type 2 diabetes discontinued a GLP-1 receptor agonist within one year.